Erythropoietic protoporphyria

Infobox_Disease
Name = Erythropoietic protoporphyria


Caption =
DiseasesDB = 4484
ICD10 = ICD10|E|80|0|e|70 (ILDS E80.010)
ICD9 = ICD9|277.1
ICDO =
OMIM = 177000
MedlinePlus =
eMedicineSubj = derm
eMedicineTopic = 473
MeshName = Protoporphyria,+Erythropoietic
MeshNumber = C06.552.830.812

Erythropoietic protoporphyria (EPP) is a relatively mild form of porphyria, although very painful, which arises from a deficiency in the enzyme ferrochelatase, leading to abnormally high levels of protoporphyrin in the tissue. The severity varies significantly from individual to individual.

Both autosomal dominant and autosomal recessive inheritance have been reported with this disorder. [cite journal |pmid=9585598 |year=1998 |author=Rüfenacht UB, Gouya L, Schneider-Yin X, Puy H, Schäfer BW, Aquaron R, Nordmann Y, Minder EI, Deybach JC |title=Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria |volume=62 |issue=6 |pages=1341–52 |pmc=1377149 |doi=10.1086/301870 |journal=American journal of human genetics]

Presentation

A common symptom is very painful photosensitivity, manifesting itself as a burning sensation on the surface of the skin. This usually first presents in childhood, and most often affects the face and the upper surfaces of the hands and feet. Prolonged exposure to the sun can lead to edema and blistering. After many years, chronically sun-exposed skin may become thick and wrinkled. People with EPP are also at increased risk to develop gallstones [MerckHome|12|160|d] . In a small percentage of cases, protoporphyrin accumulates to toxic levels in the liver, leading to liver failure.

Treatment and prognosis

There is no cure for this disorder; however, symptoms can usually be managed by the simple expedient of limiting sun exposure. Protective clothing is also very helpful; however, since the photosensitivity results from light in the visible spectrum, most sunscreens (with the exception of light-reflecting substances such as zinc oxide) are of little use. Some individuals can decrease their sun sensitivity with daily doses of beta carotene; others gradually build a protective layer of melanin by regularly exposing themselves for short times to ultraviolet radiation. The most severe cases are sometimes treated with liver transplants.

Experimental treatments

Recently, an Australian pharmaceutical company has begun Phase III clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name "afamelanotide", formerly CUV1647)Cite web|url=http://www.clinuvel.com/resources/pdf/asx_announcements/2008/20080617WHOGenericName.pdf|title=World Health Organisation assigns CUV1647 generic name|accessdate=2008-06-17|publisher=Clinuvel|year=2008|format=PDF] for EPP. [http://www.bad.org.uk/public/leaflets/erythropoietic.asp Erythropoietic - British Association of Dermatologists] ] PDF| [http://www.clinuvel.com/resources/pdf/asx_announcements/2007/07-04-11ApprovalEPPPhIII.pdf Clinuvel receives approval to begin Phase III trials in EPP] |273 KB]

History

Erythropoietic protoporphyria was first identified in 1960 by Magnus "et al" at the St John's Institute of Dermatology in London. [cite journal |author=Magnus IA, Jarrett A, Prankerd TA, Rimington C |title=Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia |journal=Lancet |volume=2 |issue=7200 |pages=448–51 |year=1961 |pmid=13765301 |doi= |url=]

References

External links

*
*